Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 1464 (Tablet) in Hyperlipemic Healthy Male Subjects

Inclusion Criteria: * Healthy male Caucasian subjects as determined by results of screening * Written informed consent in accordance with GCP and local legislation given * Age \>= 18 and \<= 65 years * Broca \>= - 20% and \<= + 30% * LDL-cholesterol level \>= 3.3 mmol/L at pre-screening and at the two screening visits Exclusion Criteria: * Any finding of the medical examination. (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance * Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal (including thyroid) disorder * Surgery of the gastro-intestinal tract (except appendectomy) * Disease of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders * History or orthostatic hypotension, fainting spells or blackouts * Chronic or relevant acute infections * History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged the investigator * Intake of drugs with a long half-life (\> 24 hours) (\<= 1 month prior to administration or during the trial) * Use of any drugs which might influence the result of the trial (\<= 10 days prior to administration or during the trial) * Participation in another trial with an investigational drug (\<= 2 month prior to administration or during the trial) * Smoker (\> 10 cigarettes or \> 3 cigars or \>3 pipes/day) * Inability to refrain from smoking during the period of the study * Alcohol abuse (\>60/g/day) * Drug abuse * Blood donation (\>400ml \<=1 month prior to administration) * Excessive physical activities (\<=5 days prior to administration) * Any laboratory value outside the normal range of clinical relevance * LDL - cholesterol screening measurements day -1 and day -7 the different between these two values exceed 12% of the higher dose * subjects who are vegetarian Eye-lens * Cataract extraction in one or both eyes deemed likely within 2 years ("senile", non-idiopathic will not automatically exclude patients from participation) * Lens Opacities Classification System (LOCS) III grade \>3.0 (for nuclear opalescence or cortical grad) \>0.5 (for posterior sub capsular grad) * Log MAR Bailey-Lovie visual acuity \>0.5 * Corneal or conjunctival problems which would preclude lens photography * Shallow anterior chamber with risk of angle-closure glaucoma * Pupil will not dilate to at least 6 mm * Visually significant fundus pathology in clinician's judgment * Amblyopia, optic nerve disease, iritis, history of eye surgery, argon or YAG laser, major eye trauma, extended use (daily for \>3 month) of ocular or systemic corticosteroid treatment , use of anticoagulants, or glaucoma therapy, or participation in another clinical trial investigation an anti-cataract or cataractogenic formulation within the last year